Methods and compositions for inhibiting or preventing the skin irritating or sensitizing effects of a skin irritating or sensitizing component of a dermal or transdermal drug delivery system are disclosed. The composition comprises a mast cell degranulating agent which is capable of inducing a state of immunological tolerance to the skin sensitizing agent by delivery prior to, or at the onset of transdermal drug delivery. Such an agent, preferably cis-urocanic acid or an analogue or metabolite thereof, can be administered before, during or after each transdermal drug delivery to achieve immune tolerance countersensitization. Alternatively, the agent can be used to induce countersensitization. The agent is preferably capable of permeating the epidermis and is administered transdermally. Novel methods and compositions comprising cis-urocanic acid or an analogue or metabolite thereof to obtain anti-inflammatory effects are also disclosed.
本发明公开了用于抑制或预防皮肤或透皮给药系统中皮肤刺激性或致敏成分的皮肤刺激或致敏效应的方法和组合物。该组合物包含一种肥大细胞脱颗粒剂,它能够在透皮给药之前或开始时通过给药诱导对皮肤致敏剂的免疫耐受状态。可以在每次透皮给药之前、期间或之后给药这种药剂,最好是顺式
尿囊酸或其类似物或代谢物,以达到免疫耐受反敏的目的。或者,也可以使用该药剂来诱导反敏。药剂最好能渗透表皮,并经皮肤给药。此外,还公开了包含顺式
尿囊酸或其类似物或代谢物以获得抗炎效果的新方法和组合物。